Bioatla® Profiled in Nature Biopharma Dealmakers

The September 2014 issue of Nature Biopharma Dealmakers focused on innovative biotech companies in the field of cancer immunotherapy, and featured a profile of Bioatla® and their Conditionally Active Biologics (CAB) technology.

With this technology antibodies can be engineered for activity only in certain microenvironments (for example the acidic microenvironment of tumor cells), thereby enhancing safety and therapeutic index. The safety of existing antibody drug conjugates can be improved, and new antibodies made to targets that are not specific enough to cancer cells to be suitable drug targets currently.